Stem Cells International / 2021 / Article / Tab 3

Review Article

Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update

Table 3

MSC-EV treatment trials in COVID-19 registered on Clinical Trials. The treatment of COVID-19 disease, including trial numbers, source of EVs, routes of administration, and primary endpoints.

Trial ID no.StatusResponsible countrySource of extracellular vesiclesAdministrationPrimary endpoints

NCT04276987CompletedChinaExosome derived from allogenic adipose mesenchymal stem cellsInhalationAdverse reaction
NCT04491240Completed has resultsRussian FederationMSC exosomesInhalationAdverse events
NCT04493242Not recruitingUnited StatesBone marrow-derived extracellular vesiclesIVAll-cause mortality
NCT04602442Enrolling by invitationRussian FederationMesenchymal stem cell exosomesInhalationAdverse events during trial
NCT04657458AvailableUnited StatesBone marrow-derived extracellular vesiclesIVNot recorded
NCT04798716Not recruitingUnited StatesMSC exosomesIVAdverse events

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.